TickerTalks
Browse all tickers →
TickerTalks›$DHR
DHDHR

Danaher Corporation

Strong FundamentalsStrong FundamentalsRevenue growing 4% YoY at strong marginsStreet coverage with positive forward estimatesQuiet on X (87 mentions/wk)
$DHR·$144B·Medical - Diagnostics & Research·Healthcare
$213.56-1.2%YTD-14.9%1Y+5.3%
Mentions · last 7 days
2026-08-21: 9 posts2026-08-22: 4 posts2026-08-23: 7 posts2026-08-24: 14 posts87+6%
Price updated 1h ago·X counts updated 7d ago
DHDHR
$DHRDanaher Corporation
$213.56-1.16%87 posts+6%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $DHR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-08-29

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Danaher with a fresh CEO (Julie Montgomery in) — quality life-sciences compounder ready for a leadership-refresh re-rating.

Danaher Corporation is a leading life-sciences and diagnostics conglomerate — Beckman Coulter, Cepheid, Cytiva, Leica, Radiometer, plus the Environmental & Applied Solutions segment. The setup is a real-business quality name coiled on a specific leadership catalyst.

  • The CEO change is the specific catalyst: Danaher announced August 3 that its Board appointed Julie Sawyer Montgomery as President and CEO effective October 1 — the crowd is cheering the change ("Julie in, 'Eeyore' out") as +2% AH reaction and DHR is appearing on liquid-leader watchlists with technical-accumulation setups.
  • The core P&L is compounding as expected: Q1 revenue grew 3.7% YoY to $5.95B at a 60% gross margin and 23% operating margin, Q2 EPS beat at $1.94 vs $1.85 consensus, and the sell side models FY26 EPS at ~$8.49 rising to ~$10.16 in 2028 — mid-single-digit revenue growth with mid-teens EPS growth from margin expansion.
  • The Rales-family equity-grant tape is genuine: Steven and Mitchell Rales each received 1.5M shares in an A-Award on August 4 (worth ~$195M each), and Jonathan Leiken received a $17.9M A-Award — combined a very large equity award to the founding family plus C-suite that some in the sample flagged as frustrating, but is likely tied to the CEO transition compensation planning.

The setup is a real-business quality life-sciences compounder coiled on the CEO transition plus the recent Bamco 315,789-share purchase — the October 20 Q3 print is the referee, and the market needs continued mid-single-digit revenue growth plus updated Biotechnology segment strength. A clean beat plus a first Montgomery-led guidance framing extends the coil up toward $240; a soft Biotechnology or Diagnostics segment print cools the tape from current levels.

Agrees with X sentimentThe bullish X read on the CEO change (Julie in, 'Eeyore' out) with the +2% AH reaction, DHR appearing on liquid-leader watchlists, and technical-accumulation setups is factually consistent with the announcement. The Rales-family equity-grant frustration is a real minority signal but the $195M x 2 A-Awards likely reflect long-cycle governance compensation planning tied to the CEO transition, which the sample is right to note but the market has repriced modestly.

What to watch: The October 20 Q3 earnings — need continued mid-single-digit revenue growth, updated Biotechnology segment strength, and the first Montgomery-led guidance framing (though effective Oct 1). A soft Biotechnology or Diagnostics segment print cools the tape from current levels; a clean beat plus a first Montgomery-led guidance framing extends the coil up toward $240.

On the calendar: 2026-10-20 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment40 posts analyzed · as of 2026-08-11

Danaher posters cheer the CEO change (Julie in, 'Eeyore' out) as a +2% AH reaction, with DHR appearing on liquid-leader watchlists and technical accumulation setups. Some Rales-family equity-grant frustration. Sentiment is broadly bullish on the leadership refresh.

Read the AI verdict + X sentiment for $DHR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Operates life science instrument businesses (Cytiva, Sciex) and diagnostics platforms across biotech and environmental monitoring.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $DHR.

Medical - Diagnostics & Research · Healthcare

Diagnostic testing volumes are normalizing post-COVID elevated baseline; liquid biopsy and genomic sequencing are the structural growth areas. Reimbursement rate changes (CMS updates) are the primary margin risk for established lab businesses.

What this means for $DHR

Partial — branded pharmaceutical revenue is exposed to patent cliff dynamics and GLP-1 category cannibalization; Danaher Corporation is a diversified global technology and science company that .

Industry benchmark

21-name peer basket
+37.9%YTD
+82.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
35.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
5.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
21.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
60.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 21, 2026$1.94$1.85+4.9%
Q1 2026Apr 21, 2026$2.06$1.94+6.2%
Q4 2025Jan 28, 2026$2.23$2.16+3.2%
Q3 2025Oct 21, 2025$1.89$1.72+9.9%
Next earningsTue, Oct 20·consensus EPS $1.96

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$6.0B+3.7%60.3%22.6%$1.45$1.1B
Q4 FY25$6.8B+4.6%58.0%22.0%$1.69$1.7B
Q3 FY25$6.1B+4.4%58.2%19.1%$1.28$1.4B
Q2 FY25$5.9B+3.4%66.6%20.1%$0.77$1.1B

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$26.2B$25.6B – $26.4B$8.49$8.43 – $8.5116
FY27$28.2B$27.0B – $28.8B$9.25$9.12 – $9.3516
FY28$30.0B$29.3B – $30.8B$10.16$9.13 – $10.6614
FY29$32.1B$31.4B – $32.6B$11.27$10.96 – $11.509
FY30$33.9B$33.1B – $34.4B$12.48$12.13 – $12.7413

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.67%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+6.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 625.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.805-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 21Rainer BlairCEO58.3K sh$12.7MSellMay 1Alan G SpoonDirector1.4K sh$237K
+ 38 other (31 awards · 4 inkinds · 3 exempts) in window

See when $DHR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeAug 38-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Danaher Corporation (DHR) announced on August 3, 2026 that its Board appointed Julie Sawyer Montgomery as President and Chief Executive Officer, effective October 1, 2026. The appointment was disclosed via 8-K Items 5.02, 7.01, and 8.01. Compensation details are referenced in related exhibits. The announcement marks a major C-suite succession at Danaher, a $170B+ market-cap life sciences and diagnostics conglomerate. Montgomery's background and compensation arrangements will be furnished in related materials.

8-KMaterial debt obligationJun 38-K — Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

DHR (DHR) disclosed the creation of a direct financial obligation under 8-K Item 2.03, reporting a new notes. The obligation totals approximately $0 at 0.200%. Item 2.03 is triggered when a company creates or assumes a material direct financial obligation, including borrowings under credit agreements, issuance of debt securities, or similar instruments. This disclosure ensures investors are promptly informed about new claims on company cash flows and changes to the capital structure.

8-KOfficer or director changeMay 78-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

DHR disclosed a personnel change (8-K Item 5.02, dated 2026-05-07). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KMaterial agreementApr 298-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

DHR entered into a material definitive agreement (8-K Item 1.01, dated 2026-04-29). Rate: 3.250%. Due 2028. Material definitive agreement — investors should review the full exhibit for covenants, conditions, and use of proceeds.

424B5Prospectus supplement (offering)Apr 23424B5
AI summary

DHR filed a 424B5 prospectus supplement dated 2026-04-23, representing an active capital markets transaction. proceeds from the offering of the notes to fund a portion of the cash consideration payable for, and. This represents immediate dilution to existing shareholders.

424B5Prospectus supplement (offering)Apr 22424B5
AI summary

DHR filed a 424B5 prospectus supplement dated 2026-04-22, representing an active capital markets transaction. proceeds from the offering of the notes to fund a portion of the cash consideration payable for, and. This represents immediate dilution to existing shareholders.

8-KMaterial agreementApr 178-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

DHR entered into a revolving credit facility (8-K Item 1.01, dated 2026-04-17). Counterparty: Bank of America, N.A.. Size: approximately $5.0 billion. Rate: 0.50%. Material definitive agreement — investors should review the full exhibit for covenants, conditions, and use of proceeds.

+ 16 other (2 earnings 8-Ks · 2 10-Qs · 2 S-8s · 2 13Gs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Ausdal Financial Partners Inc. Buys Shares of 2,452 Danaher Corporation $DHRdefenseworld.net·4d ago315,789 Shares in Danaher Corporation $DHR Purchased by Bamco Inc. NYdefenseworld.net·5d agoDanaher Rides on Strength in Biotechnology Segment: Will It Sustain?zacks.com·6d agoCancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.247wallst.com·7d agoAlly Financial Inc. Invests $8.95 Million in Danaher Corporation $DHRdefenseworld.net·8d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$TWST$PSNL$A$ILMN$NTRA$GH$TMO
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport